Sign Out
CYP3A4 Inhibitors: Co-administration of AQUIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of atogepant in healthy subjects (see Pharmacology under Actions). The recommended dosage of AQUIPTA with concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is 10 mg once daily. No dose adjustment of AQUIPTA is needed with concomitant use of moderate or weak CYP3A4 inhibitors.
Organic anion transporting polypeptide (OATP) Inhibitors: Co-administration of AQUIPTA with single dose rifampicin [rifampin], an OATP inhibitor, resulted in a significant increase in exposure of atogepant in healthy subjects (see Pharmacology under Actions). The recommended dosage of AQUIPTA with concomitant use of strong OATP inhibitors (e.g., cyclosporine [ciclosporin]) is 10 mg.
Continue with Google